- Report
- April 2024
- 287 Pages
Global
From €7705EUR$7,950USD£6,599GBP
- Report
- August 2022
- 182 Pages
Global
From €7268EUR$7,500USD£6,225GBP
- Report
- August 2022
- 91 Pages
Global
From €3828EUR$3,950USD£3,279GBP
- Report
- January 2022
- 60 Pages
Global
From €3828EUR$3,950USD£3,279GBP
- Report
- May 2018
- 90 Pages
Global
From €2810EUR$2,900USD£2,407GBP
- Report
- August 2022
United States
From €1880EUR$1,940USD£1,610GBP
- Report
- August 2022
Global
From €766EUR$790USD£656GBP
- Report
- February 2021
Global
From €2869EUR$2,960USD£2,457GBP
- Report
- August 2021
Europe
From €3314EUR$3,420USD£2,839GBP
- Report
- August 2021
Global
From €3867EUR$3,990USD£3,312GBP
- Clinical Trials
- July 2021
- 148 Pages
Global
From €2423EUR$2,500USD£2,075GBP
- Clinical Trials
- February 2021
- 138 Pages
Global
From €2423EUR$2,500USD£2,075GBP
- Report
- September 2022
- 74 Pages
Global
From €3387EUR$3,495USD£2,901GBP
- Report
- October 2019
- 151 Pages
Global
From €10655EUR$10,995USD£9,126GBP
- Report
- September 2019
- 27 Pages
Global
From €3872EUR$3,995USD£3,316GBP
- Drug Pipelines
- July 2020
- 254 Pages
Global
From €1938EUR$2,000USD£1,660GBP
- Report
- August 2021
- 112 Pages
Global
From €3200EUR$3,537USD£2,837GBP
- Drug Pipelines
- March 2021
Global
From €1938EUR$2,000USD£1,660GBP
- Report
- May 2023
- 70 Pages
France
From €3460EUR$3,570USD£2,963GBP
- Report
- May 2023
- 79 Pages
China
From €3154EUR$3,255USD£2,702GBP
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder that causes weakness in the skeletal muscles. MG is treated with a variety of drugs, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Anticholinesterase drugs, such as pyridostigmine, are used to increase the availability of acetylcholine at the neuromuscular junction, thereby improving muscle strength. Immunosuppressants, such as azathioprine and cyclosporine, are used to reduce the production of antibodies that attack the neuromuscular junction. Immunomodulators, such as mycophenolate mofetil, are used to modulate the immune system and reduce the production of antibodies.
The Myasthenia Gravis Drug market is a subset of the Central Nervous System Drugs market. It is composed of a variety of drugs used to treat MG, including anticholinesterase drugs, immunosuppressants, and immunomodulators. Companies in the Myasthenia Gravis Drug market include Merck, Pfizer, Novartis, GlaxoSmithKline, and Teva Pharmaceuticals. Show Less Read more